Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Elekta AB's Agility Radiation Therapy Beam-Shaping Innovation For Cancer Treatments Receives U.S. 510(k) Clearance
Elekta AB announced that it has received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer. An MLC, a device made up of numerous, individual tungsten leaves, is used to shape beams of therapeutic radiation that are delivered from different angles around the patient.
Latest Developments for Elekta AB
- Elekta AB's Chairman Akbar Seddigh Declines Reelection
- Elekta AB Receives U.S. FDA 510(k) Clearance Following Launch Of New Versa HD Radiation Therapy System For Cancer Treatment
- Elekta AB Downgrades FY 2012/2013 Revenue Guidance and Updates on FY 2012/2013 Operating Profit Guidance
- Elekta AB Receives FDA Clearance for Clarity 4D Monitoring Software
Latest Key Developments in Advanced
- Hologic Inc Receives FDA Approval For New Low-dose 3D Mammography (Breast Tomosynthesis) Solution For Breast Cancer Screening
- Echo Therapeutics Inc Announces Institutional Review Board (IRB) Approval For Clinical Trial Of Symphony CGM System
- Neovasc Inc Announces Registry Data Presented At Europcr 2013 Confirms the Neovasc Reducer Improves Cardiovascular Parameters In Refractory Angina Patients
- Elekta AB's Chairman Akbar Seddigh Declines Reelection
- Share this
- Link this
- Digg this
Follow Reuters